期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

RNA干扰技术的应用新进展 被引量：4

Recent Advances in the Application of RNA Interference Techniques
下载PDF
导出
摘要 RNA干扰(RNA interference,RNAi)被发现十年来在生物研究领域已经得到了长足的发展,并且已经初步显示出了巨大的潜力。本文综述了介导SiRNA方法的研究及其在基础研究、疾病模型建立和药物研究中的最新应用进展。 RNA interference（RNAi）has made considerable development in the biology research area during the ten years since it was discovered.It has been demonstrated its huge potential initially.This article summarizes the mediating methods of SiRNA and the newest application progress of RNAi in basic research,disease model building and medicinal research.
作者 李曙芳 刘田福
机构地区 山西医科大学实验动物中心
出处 《中国实验动物学报》 CAS CSCD 2009年第1期76-79,共4页 Acta Laboratorium Animalis Scientia Sinica
关键词 RNA干扰 应用 RNAi Application
分类号 R349.62 [医药卫生—基础医学]
  • 相关文献

参考文献24

  • 1胡颖（综述）,洪蝶（综述）,谢幸（审校）,叶枫（审校）.RNA干扰机制的分子生物学研究进展[J].国际病毒学杂志,2007,14(6):185-190. 被引量：5
  • 2Boisvert ME, Simard MJ. RNAi pathway in C. elegans: the argonautes and collaborators[ J]. Curr Top Microbiol Immunol, 2008. 320:21 - 36.
  • 3Yokota T. Gene therapy of ALS with short interfering RNA[J]. Brain Nerve, 2007. 59(10): 1187-1194.
  • 4Yokota T, Iijima. S, Kubodera. T, et al. Efficient regulation of viral replication by siRNA in a non-haman primate surrogate model for hepatitis C[J]. Biochem Biophys Res Commun, 2007, 361(2): 294 - 300.
  • 5Pan Q, Liu B, Liu J, et al. Synergistic aatitumor activity of XIAP- shRNA and TRAIL expressed by oncolytic adenoviruses in experimental HCC[J]. Acta Oncol, 2007:1 - 10.
  • 6Wang Z, Li L. Adenovirus-mediated interference against collagen- specific molecular chaperone 47-kDa heat shock protein suppresses sear formation on mouse wounds [ J ]. Cell Biol Int, 2008, 32 ( 5 ) : 484 - 483.
  • 7Maehida Y, Okada T, Kurosawa M, et al. rAAV-mediated shRNA ameliorated neuropathology in Huntington disease model mouse[J]. Biochem Biophys Res Commun, 2006. 343(1):190- 197.
  • 8Chen CC, Ko TM, Ma H I, et al. Long-term inhibition of hepatitis B virus in transgenic mice by double-stranded adeno-associated virus 8- delivered short hairpin RNA[J]. Gene Ther, 2007. 14(1) :11 - 19.
  • 9Ralph GS, Radcliffe PA, Day DM, et al. Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model[J]. Nat Med, 2005. 11(4):429- 433.
  • 10Raoul C, Abbas-Terki T, Bensadoun JC, et al. Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS[J], Nat Med, 2005, 11(4) : 423 - 428.

二级参考文献33

  • 1Atar O,Avraham K B.Therapeutics of hearing loss:expectations vs reality.Drug Discov Today,2005,10:1323-1330.
  • 2Izumikawa M,Minoda R,Kawamoto K,et al.Auditory hair cell replacement and hearing improvement by Atoh1 gene therapy in deaf mammals.Nat Med,2005,11:271-276.
  • 3Chen P,Segil N.p27(Kip1) links cell proliferation to morphogenesis in the developing organ of Corti.Deve-lopment,1999,126:1581-1590.
  • 4Lehrman S.Virus treatment questioned after gene therapy death.Nature,1999,401:517-518.
  • 5Gore M E.Adverse effects of gene therapy:gene therapy can causeleukaemia:no shock,mild horror but a probe.Gene Ther,2003,10:4-4.
  • 6Wareing M,Mhatre A N,Pettis R,et al.Cationic liposome mediated transgene expression in the guinea pig cochlea.Hear Res,1999,128:61-69.
  • 7Jero J,Mhatre A N,Tseng C J,et al.Cochlear gene delivery through an intact round window membrane in mouse.Hum Gene Ther,2001,12:539-548.
  • 8Staecker H,Li D,O'Malley B W Jr,et al.Gene expression in the mammalian cochlea:a study of multiple vector systems.Acta Otolaryngol,2001,121:157-163.
  • 9Lalwani A K,Jero J,Mhatre A N.Current issues in cochlear gene transfer.Audiol Neurootol,2002,7:146-151.
  • 10Alakhov V,Klinski E,Lemieux P,et al.Block copolymeric biotransport carriers as versatile vehicles for drug delivery.Exp Opin Biol Ther,2001,1:583-602.

共引文献4

同被引文献34

  • 1Gressner OA,Gressner AM. Connective tissue growth factor:a fibrogenic master switch in fibrotic liver diseases. Liver Int, 2008,28(8):1065-1079.
  • 2Bora RS,Gupta D,Mukkur TK,et al. RNA interference therapeutics for cancer:Challenges and opportunities. Mol Med Report, 2012,6( 1 ):9-15.
  • 3Tomari Y,Zamore PD. Perspective:Machines for RNAi. Genes Dev,2005,19(5):517.
  • 4Tche D,Boqdan F,Pisoschi C,et al. Evidence for the involvement of TGF-131-CTGF axis in liver fibrogenisis secondary to hepatic viral infection. Rom J Morphol Embryol, 2011 , 52( lsuppl ) :409-412.
  • 5Murphy G.Tissue inhibitors of metalloproteinases. Genome Biol, 2011,12( 11 ):233.
  • 6Hemmann S,Graf J,Roderfeld M,et al. Expression of MMPs and TIMPs in liver fibrosis-asystematie review with speeial emphasis on anti-fibrotie strategies. J Hepatol,2007,22(5): 955-975.
  • 7Rudolph C, Roseneeker J. Formation of solid lipid nanopartiele (SLN)-gene vector complexes for transfeetion of mammalian cells in vitro. Cold Spring Harb Protoc,2012,25(3):357-360.
  • 8Munitz A, Bachelet I, Eliashar R, et al. CD48 Is an Allergen and IL3-Induced Activation Molecule on Eosinophils. J Immunol,2006, 177(1): 77-83.
  • 9Melo RC, Spencer LA, Dvorak AM, et al. Mechanisms of eosinophil secretion : large vesiculotubular carriers mediate transport and release of granule-derived eytokines and other proteins. J. Leukoc. Biol, 2008,83 (2) :229-236.
  • 10Shi HZ. Eosinophils function as antigen-presenting cells. J. Leukoe. Biol, 2004, 76(3): 520-527.

引证文献4

二级引证文献12

中国实验动物学报
2009年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部